Actinogen Medical LimitedASX: ACW

Actinogen prioritizes Alzheimers Disease & Depression

· Issued by Actinogen Medical Limited

Filed with ASX · · 3 pages · English

Sydney, 4 May 2022. Actinogen Medical ASX: ACW (“ACW” or “the Company”)announces that following strongly positive results for attention and working memory (cognition) in its recent double-blind XanaMIA Part A trial, it has conducted a reassessment of its priorities and planned expenditures, resulting in the following strategic adjustments to: • Prioritize the Alzheimer’s Disease (AD) and Major Dep

Actinogen Medical Limited on 6ix

In the deck

Story so far

Earlier from Actinogen Medical

Later from Actinogen Medical

All Actinogen Medical news releases